Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

AstraZeneca

Status: Active, not recruiting

Conditions: Lung Neoplasms; Carcinoma, Bronchogenic; Thoracic Neoplasms; Lung Diseases; Neoplasms; Neoplasms by Site; Respiratory Tract Diseases; Carcinoma, Non-Small-Cell Lung; Bronchial Neoplasms; Respiratory Tract Neoplasms

Study type: Observational

Funder types: Industry

Identifiers

NCT06494241

D5161L00048

Details and patient eligibility

About

To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.

Full description

The primary objective of this study is to assess the implementation of standardized diagnosis and treatment practice in oncology departments of Small/Middle tier cities and County hospitals, after standardized education and implementation of lung cancer clinical practice guidelines for oncology physicians.

Enrollment: 1,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥18 years, at the time of signing the informed consent.
• ECOG performance status 0-2.
• Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC.

Exclusion criteria

• Be participating in other intervention clinical trials.
• Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
• Previous enrolment in the other QIP study.